Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

1.88USD
10:47am EST
Change (% chg)

$-0.03 (-1.57%)
Prev Close
$1.91
Open
$1.91
Day's High
$1.94
Day's Low
$1.85
Volume
54,765
Avg. Vol
458,334
52-wk High
$3.58
52-wk Low
$1.50

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 2.06
Market Cap(Mil.): $258.21
Shares Outstanding(Mil.): 125.35
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -0.20 -- --
ROI: -183.19 0.60 13.80
ROE: -- -2.18 15.29

Former Aveo Pharmaceuticals CFO misled investors - jury

A federal jury in Boston on Tuesday found Aveo Pharmaceuticals Inc's former chief financial officer liable for defrauding investors by hiding bad news about the biotech's efforts to obtain regulatory approval for a kidney cancer drug. Following a two-week trial, jurors found in favor of the U.S. Securities and Exchange Commission, which had accused David Johnston of failing to disclose that the U.S. Food and Drug Administration had recommended the biotech conduct another clinical trial for the d

Nov 21 2018

Ex-Aveo Pharmaceuticals CFO takes stand in SEC fraud trial

Aveo Pharmaceuticals Inc's ex-chief financial officer, who is on trial for allegedly misleading investors by hiding bad news about the biotech's efforts to obtain regulatory approval for a kidney cancer drug, acknowledged on Tuesday that he never disclosed that the U.S. Food and Drug Administration had recommended the drugmaker conduct another clinical trial.

Nov 13 2018

Ex-Aveo CFO wants SEC blocked from arguing he did not rely on lawyers

Aveo Pharmaceuticals Inc's ex-chief financial officer has asked a judge to block U.S. securities regulators from arguing at his trial that he did not rely on lawyers' advice to decide what to disclose about the company's efforts to gain approval for a cancer drug.

Nov 12 2018

SEC accuses ex-Aveo Pharmaceuticals CFO of fraud as trial begins

A lawyer for the Securities and Exchange Commission on Tuesday told jurors in Boston that Aveo Pharmaceuticals Inc's former chief financial officer misled investors by hiding bad news about the biotech's efforts to obtain regulatory approval for a kidney cancer drug.

Nov 06 2018

Earnings vs. Estimates